argenx Reveals FDA Nod for VYVGART Hytrulo in Treating Chronic Inflammatory Demyelinating Polyneuropathy.

Takeda has revealed that the European Commission has given its approval for FRUZAQLA (fruquintinib) to be used as a monotherapy for adult patients suffering from metastatic colorectal cancer.

Bristol Myers Squibb reveals that the U.S. FDA has granted accelerated approval for KRAZATI® (adagrasib) combined with Cetuximab for adults with previously treated, advanced, or metastatic colorectal cancer (CRC) with the KRAS G12C mutation.

Zealand Pharma reveals favorable topline outcomes from the 16-week Phase 1b trial with escalating doses of long-acting amylin analog petrelintide.

Kyverna's KYV-101 gets U.S. FDA IND approval for treating patients with hard-to-treat Stiff-Person Syndrome in the KYSA-8 Phase 2 study.

Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn’s disease.

Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel).

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China.

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a).

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above.

FDA Greenlights Merck’s KEYTRUDA® (pembrolizumab) Combined with Carboplatin and Paclitaxel for Treating Adults with Advanced or Recurrent Endometrial Cancer.